Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
1.840
-0.220 (-10.68%)
Dec 5, 2025, 4:00 PM EST - Market closed
Artelo Biosciences Employees
Artelo Biosciences had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,081,833
Market Cap
3.71M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARTL News
- 23 days ago - Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer - GlobeNewsWire
- 5 weeks ago - Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - GlobeNewsWire
- 7 weeks ago - Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit - GlobeNewsWire
- 2 months ago - Artelo Biosciences Announces Closing of $2.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Artelo Biosciences Announces Pricing of $2.0 Million Public Offering - GlobeNewsWire
- 2 months ago - Artelo Biosciences Announces Proposed Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference - GlobeNewsWire